RaySearch Laboratories

Aging Population And AI Integration Will Expand Oncology Market

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

16 May 25

Updated

20 Aug 25

n/a

AnalystConsensusTarget's Fair Value

n/a

6.1%

0.4%

6.1%

0.4%

You can edit this narrative until Aug 20 11:10 AM. Then, changes will post as Updates.

Author's Valuation

SEK 36538.1% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on 20 Aug 25

Fair value Increased 6.31%

RaySearch Laboratories’ consensus analyst price target was raised to SEK365.00, primarily reflecting a higher anticipated future P/E multiple, indicating improved growth or earnings expectations. What's in the News RaySearch will showcase major innovations at AAPM 2025, including advanced adaptive replanning, AI-driven image segmentation, and upgraded Plan Explorer in RayStation; RayCare and RayIntelligence integrations and workflows will be spotlighted.

AnalystConsensusTarget Fair Value

SEK 365

38.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

13.93%

Healthtech revenue growth rate

9.61%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.30%

Calculation

SEK 433.53m

Earnings '28

34.07x

PE Ratio '28

SEK 14.77b

Market Cap '28

SEK 14.77b

Market Cap '28

34.28m

No. shares '28

SEK 430.87

Share Price '28

SEK 430.87 Share Price '28

Discounted to 2025 @ 5.98% p.a.

SEK 361.99

Fair Value '25